The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.

abstract：INTRODUCTION:Thermo transient receptor potential (thermoTRP) channels are some of the most intensely pursued therapeutic targets of the past decade. They are considered promising targets of numerous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, TRPM8 and TRPA1, have re...

journal_title：Expert opinion on investigational drugs

authors： Fernández-Carvajal A,González-Muñiz R,Fernández-Ballester G,Ferrer-Montiel A

更新日期：2020-11-01 00:00:00

abstract：:Asthma and chronic obstructive pulmonary disease (COPD) are diseases of the airways with an underlying inflammatory component. The prevalence and healthcare burden of asthma and COPD is still rising and is predicted to continue to rise in the current century. The beta-agonists and corticosteroids form the basis of the...

journal_title：Expert opinion on investigational drugs

authors： Hele DJ,Belvisi MG

更新日期：2003-01-01 00:00:00

abstract：:Zolmitriptan is a new oral acute treatment for migraine. It is a selective and potent agonist at the serotonin (5-HT)(1B/1D) receptor and was developed to improve on the oral bioavailability, tissue selectivity and CNS penetration of earlier compounds. Animal studies confirmed that these objectives had been attained. ...

journal_title：Expert opinion on investigational drugs

authors： Rolan PE,Martin GR

更新日期：1998-04-01 00:00:00

abstract：:Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

journal_title：Expert opinion on investigational drugs

authors： Kreitman RJ

更新日期：1998-09-01 00:00:00

abstract：:Introduction: Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all pharmacologic treatments for OA are directed toward pain management. Lorecivivint (LOR) ...

journal_title：Expert opinion on investigational drugs

authors： Sabha M,Siaton BC,Hochberg MC

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:Melanoma is one of the most aggressive forms of cutaneous malignancies displaying a substantial mortality rate among the various forms of skin cancers. The management of patients with advanced melanoma poses a significant challenge considering that the disease is refractory to most conventional therapies. ...

journal_title：Expert opinion on investigational drugs

authors： Bhatia S,Emdad L,Das SK,Hamed H,Dent P,Sarkar D,Fisher PB

更新日期：2014-04-01 00:00:00

abstract：:The main cause of illness and death after the first year of heart transplantation is vasculopathy of the cardiac allograft, probably initiated by early immunological and non-immunological endothelial damage. The incidence of multiple episodes of grade 3A rejection 6 months after primary heart transplantation was lower...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-02-01 00:00:00

abstract：:The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for pro...

journal_title：Expert opinion on investigational drugs

authors： Van Cott KE,Velander WH

更新日期：1998-10-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established. AREAS COVERED IN THIS REVIEW:We herein review ...

journal_title：Expert opinion on investigational drugs

authors： Sarigianni M,Tsapas A,Mikhailidis DP,Kaloyianni M,Koliakos G,Fliegel L,Paletas K

更新日期：2010-12-01 00:00:00

abstract：INTRODUCTION:Due to improvements in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), several target drugs have been and are being developed. One of the possible targets in SLE is co-stimulation between antigen-presenting cells and T cells. Abatacept is a co-stimulation moderator approved for...

journal_title：Expert opinion on investigational drugs

authors： Pimentel-Quiroz VR,Ugarte-Gil MF,Alarcón GS

更新日期：2016-01-01 00:00:00

abstract：:The tremendous increase in the global prevalence of Type 2 diabetes (T2D) and its conglomeration of metabolic disorders has dramatically intensified the search for innovative therapies to fight this emerging epidemic. Over the last decade, the family of nuclear receptors, especially the peroxisome proliferator-activat...

journal_title：Expert opinion on investigational drugs

authors： Savkur RS,Miller AR

更新日期：2006-07-01 00:00:00

abstract：INTRODUCTION:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progres...

journal_title：Expert opinion on investigational drugs

authors： Galimberti D,Scarpini E

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Patients with myelofibrosis (MF) have no effective treatment option after the failure of approved JAK inhibitor (JAKi) therapy. Non-JAK inhibitors (non-JAKi) that target non-canonical molecular pathways are undergoing clinical evaluations to optimize efficacy and/or to reduce hematological toxicity of JAKi...

journal_title：Expert opinion on investigational drugs

authors： Bankar A,Gupta V

更新日期：2020-05-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Curcumin has been investigated in preclinical and translational stroke models because of its pleiotropic 'neuroprotective' activities. Since curcumin has poor blood-brain barrier (BBB) penetration following acute administration, creative medicinal chemistry has been used to modify the parent cur...

journal_title：Expert opinion on investigational drugs

authors： Lapchak PA

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. OBJECTIVE:To review papers published or presented at recent international meetings showing the results o...

journal_title：Expert opinion on investigational drugs

authors： Vento S,Cainelli F,Temesgen Z

更新日期：2008-11-01 00:00:00

abstract：BACKGROUND:Malaria continues to exact a huge toll on the health of residents of endemic countries. Thus, new approaches to prevention and treatment are needed. OBJECTIVE:To provide an update on novel therapies for the prevention of malaria. METHODS:Systematic MEDLINE search from 1956 to 2008 using the search term 'ma...

journal_title：Expert opinion on investigational drugs

authors： Bojang KA

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity. Although many currently available treatment regimens are effective, poor symptom control and refractory severe disease still represent major unmet needs. In the last years, numerous molecular therapeutic targets that inte...

journal_title：Expert opinion on investigational drugs

authors： Santus P,Radovanovic D

更新日期：2016-09-01 00:00:00

abstract：:In the last decade, transdermal delivery of testosterone (T) has been shown to be a safe and effective means of treating male hypogonadism. Transdermal T patches can provide for physiologic androgen replacement in over 90% of men with hypogonadism. In addition, T patches have been shown to be equivalent to im. T ester...

journal_title：Expert opinion on investigational drugs

authors： Amory JK,Matsumoto AM

更新日期：1998-12-01 00:00:00

abstract：INTRODUCTION:Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED:This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of...

journal_title：Expert opinion on investigational drugs

authors： Strumberg D,Schultheis B

更新日期：2012-06-01 00:00:00

abstract：:Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive im...

journal_title：Expert opinion on investigational drugs

authors： Sosnovik DE,Muller JE,Kathiresan S,Brady TJ

更新日期：2002-05-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately...

journal_title：Expert opinion on investigational drugs

authors： Pal SK,Reckamp K,Yu H,Figlin RA

更新日期：2010-11-01 00:00:00

abstract：INTRODUCTION:Currently, there is no cure available for the hereditary neurodegenerative disease proximal spinal muscular atrophy (SMA), which is the number one genetic killer in early childhood. However, growing knowledge of SMA pathophysiology has opened new avenues for potential therapeutic interventions. AREAS COVE...

journal_title：Expert opinion on investigational drugs

authors： Kaczmarek A,Schneider S,Wirth B,Riessland M

更新日期：2015-01-01 00:00:00

abstract：:The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor. Unfortunately, the majority of patients eventually experience disease progression due to drug re...

journal_title：Expert opinion on investigational drugs

authors： Sankhala KK,Papadopoulos KP

更新日期：2007-10-01 00:00:00

abstract：INTRODUCTION:Available drugs partially attenuate the hyperglycemia characteristic of diabetes. However, successful approaches to treat the root cause or to cure or prevent diabetes remain elusive. Drug discovery and development programs continue to focus on mechanisms that impact specific symptoms of diabetes. In 2014,...

journal_title：Expert opinion on investigational drugs

authors： Colca JR

更新日期：2015-01-01 00:00:00

abstract：:New bolus fibrinolytic agents derived from the recombinant human tissue plasminogen activator (t-PA) have emerged as a new means of dissolution of the occlusive thrombosis associated with acute myocardial infarction. Lanoteplase is a fibrinolytic drug derived from t-PA by deleting its fibronectin finger-like and epide...

journal_title：Expert opinion on investigational drugs

authors： Llevadot J,Guigliano RP

更新日期：2000-11-01 00:00:00

abstract：:Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

journal_title：Expert opinion on investigational drugs

authors： Ruef J,Katus HA

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

journal_title：Expert opinion on investigational drugs

authors： Thanarajasingam U,Niewold TB

更新日期：2014-10-01 00:00:00

abstract：:Introduction: Plasma kallikrein is a  mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete response of some patient...

journal_title：Expert opinion on investigational drugs

authors： Bhatwadekar AD,Kansara VS,Ciulla TA

更新日期：2020-03-01 00:00:00

abstract：:Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

journal_title：Expert opinion on investigational drugs

authors： Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

更新日期：2000-11-01 00:00:00

abstract：INTRODUCTION:The highly divergent histological heterogeneities, aggressive invasion and extremely poor response to treatment make glioblastoma (GBM) one of the most lethal and difficult cancers in humans. Among key elements driving its behavior is epidermal growth factor receptor (EGFR), however, neither traditional th...

journal_title：Expert opinion on investigational drugs

authors： Gao Q,Lei T,Ye F

更新日期：2013-08-01 00:00:00